These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Synergistic effects of D1 and D2 dopamine agonists on turning behaviour in rats. Robertson GS; Robertson HA Brain Res; 1986 Oct; 384(2):387-90. PubMed ID: 2946360 [TBL] [Abstract][Full Text] [Related]
7. Effects of inactivation of D1 dopamine receptors on stereotypic and thermic responses to quinpirole (LY 171555). Double KL; Crocker AD Neurosci Lett; 1990 Jul; 115(1):81-5. PubMed ID: 1977110 [TBL] [Abstract][Full Text] [Related]
8. Dopaminergic drugs reverse the impairment of radial-arm maze performance caused by lesions involving the cholinergic medial pathway. McGurk SR; Levin ED; Butcher LL Neuroscience; 1992 Sep; 50(1):129-35. PubMed ID: 1357591 [TBL] [Abstract][Full Text] [Related]
9. The D2 agonist quinpirole potentiates the discriminative stimulus effects of the D1 agonist SKF 38393. Williams JE; Woolverton WL Pharmacol Biochem Behav; 1990 Oct; 37(2):289-93. PubMed ID: 1981936 [TBL] [Abstract][Full Text] [Related]
10. Stimulatory effects of quinpirole hydrochloride, D2-dopamine receptor agonist, at low concentrations on prolactin release in female rats in vitro. Tagawa R; Takahara J; Sato M; Niimi M; Murao K; Ishida T Life Sci; 1992; 51(10):727-32. PubMed ID: 1355255 [TBL] [Abstract][Full Text] [Related]
11. Excitatory neuronal responses to dopamine in the cerebral cortex: involvement of D2 but not D1 dopamine receptors. Bradshaw CM; Sheridan RD; Szabadi E Br J Pharmacol; 1985 Oct; 86(2):483-90. PubMed ID: 2932196 [TBL] [Abstract][Full Text] [Related]
12. Ontogenic homologous supersensitization of quinpirole-induced yawning in rats. Kostrzewa RM; Brus R Pharmacol Biochem Behav; 1991 Jun; 39(2):517-9. PubMed ID: 1682952 [TBL] [Abstract][Full Text] [Related]
13. A D2 dopamine receptor agonist disrupts sensorimotor gating in rats. Implications for dopaminergic abnormalities in schizophrenia. Peng RY; Mansbach RS; Braff DL; Geyer MA Neuropsychopharmacology; 1990 Jun; 3(3):211-8. PubMed ID: 2141986 [TBL] [Abstract][Full Text] [Related]
14. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation. Hu XT; White FJ Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677 [TBL] [Abstract][Full Text] [Related]
15. Yohimbine's anxiogenic action: evidence for noradrenergic and dopaminergic sites. Johnston AL; File SE Pharmacol Biochem Behav; 1989 Jan; 32(1):151-6. PubMed ID: 2567522 [TBL] [Abstract][Full Text] [Related]
16. TL 333, a benzhydro[g]quinoline, stimulates both D-1 and D-2 dopamine receptors: implications for the selectivity of LY 141865 towards the D-2 receptor. Itoh Y; Goldman ME; Kebabian JW Eur J Pharmacol; 1985 Jan; 108(1):99-101. PubMed ID: 3979438 [TBL] [Abstract][Full Text] [Related]
17. Dopamine D-1 receptor agonists combined with the selective D-2 agonist quinpirole facilitate the expression of oral stereotyped behaviour in rats. Arnt J; Hyttel J; Perregaard J Eur J Pharmacol; 1987 Jan; 133(2):137-45. PubMed ID: 2949991 [TBL] [Abstract][Full Text] [Related]
18. Anticonvulsant effects of ipsilateral but not contralateral microinjections of the dopamine D2 agonist LY 171555 into the nucleus accumbens of amygdala-kindled rats. Wahnschaffe U; Löscher W Brain Res; 1991 Jul; 553(2):181-7. PubMed ID: 1681980 [TBL] [Abstract][Full Text] [Related]